| Date | Title | Description |
| 04.01.2022 | Aravive Announces $10.0 Million Investment by Eshelman Ventures, LLC and Appointment of Dr. Eshelman as Executive Chairman of the Aravive Board of Directors | HOUSTON, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that the company’s Chairman, Fred Eshelman, Pharm.D... |
| 04.01.2022 | Aravive : Announces $10.0 Million Investment by Eshelman Ventures, LLC and Appointment of Dr. Eshelman as Executive Chairman of the Aravive Board of Directors - Form 8-K | Aravive Announces $10.0 Million Investment by Eshelman Ventures, LLC and Appointment of Dr. Eshelman as Executive Chairman of the Aravive Board of Directors
Houston, TX, January 3, 2022 - Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage ... |
| 03.01.2022 | Aravive Announces $10.0 Million Investment by Eshelman Ventures, LLC and Appointment of Dr. Eshelman as Executive Chairman of the Aravive Board of Directors | HOUSTON, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that the company’s Chairman, Fred Eshelman, Pharm.D... |
| 12.11.2021 | Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept (AVB-500) in Combination with Cabozantinib for Treatment of Clear Cell Renal Cell Carcinoma - Form 8-K | Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept
(AVB-500) in Combination with Cabozantinib for Treatment of Clear Cell Renal Cell Carcinoma
7 of 16 (44%) patients achieved best overall response of part... |
| 12.11.2021 | Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept (AVB-500) in Combination with Cabozantinib for Treatment of Clear Cell Renal Cell Carcinoma | 7 of 16 (44%) patients achieved best overall response of partial response
Confirmed response in 5 of 7 (71%) patients who had at least 16 weeks of follow-up
14 of 16 (88%) patients demonstrated tumor decrease from baseline
Batiraxcept has b... |
| 09.11.2021 | Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept (AVB-500) in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma to - Form 8-K | Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating
Batiraxcept (AVB-500) in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma to
be Presented at 2021 Society for Immunotherapy of Cancer Annual Meeting
... |
| 09.11.2021 | Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept (AVB-500) in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma to be Presented at 2021 Society for... | 3 of 5 (60%) patients achieved a partial response
All 5 patients treated demonstrated tumor decrease from baseline
Batiraxcept has been generally well-tolerated with no dose-limiting toxicities
Aravive to host conference call and webcast on... |
| 07.05.2013 | Arav Receives €9M Minority Investment from Vertis | Arav, a near Naples, Italy-based clothing manufacturer, received a €9m minority investment from Vertis Sgr.
The proceeds from the deal, which will include two different capital increases, will enable the company to continue to grow in Italy... |
